BRIACELL THERAPEUTICS CORP (BCTX) Forecast, Price Target & Analyst Ratings

NASDAQ:BCTX • CA1079303071

4.3 USD
-0.04 (-0.92%)
At close: Mar 12, 2026
4.33 USD
+0.03 (+0.7%)
After Hours: 3/12/2026, 8:24:34 PM

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BRIACELL THERAPEUTICS CORP (BCTX).

Forecast Snapshot

Consensus Price Target

Price Target
N/A
N/A
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release DateJun 15, 2026
PeriodQ3 / 2026
EPS Estimate-$2.77
Revenue Estimate
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
80.00%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
N/A
Upside
N/A
From current price of $4.30 to mean target of N/A, Based on 5 analyst forecasts
Low
N/A
Median
N/A
High
N/A

Price Target Revisions

1 Month
0.00%
3 Months
0.00%

Price Target Summary

→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

BCTX Current Analyst RatingBCTX Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0.5 1 1.5 2 2.5

Analyst Ratings History

BCTX Historical Analyst RatingsBCTX Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -10 -9 -8 -7 -6 -5 -4 -3 -2 -1 0 1 2 3 4

Analyst Ratings Consensus

ChartMill Buy Consensus
80.00%
BCTX was analyzed by 5 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about BCTX.
In the previous month the buy percentage consensus was at a similar level.
Only 5 analysts analyzed BCTX. So this is just the average opinion of a couple of analysts.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2025-08-27HC Wainwright & Co.Maintains Buy -> Buy
2025-04-22HC Wainwright & Co.Reiterate Buy -> Buy
2025-02-03HC Wainwright & Co.Maintains Buy -> Buy
2024-12-12HC Wainwright & Co.Reiterate Buy -> Buy
2024-12-03HC Wainwright & Co.Reiterate Buy -> Buy
2024-10-03HC Wainwright & Co.Reiterate Buy -> Buy
2024-09-19HC Wainwright & Co.Maintains Buy -> Buy
2024-09-11HC Wainwright & Co.Reiterate Buy -> Buy
2024-06-04HC Wainwright & Co.Reiterate Buy -> Buy
2024-05-24HC Wainwright & Co.Reiterate Buy -> Buy
2023-12-28HC Wainwright & Co.Reiterate Buy -> Buy
2023-10-03HC Wainwright & Co.Maintains Buy -> Buy
2023-06-28HC Wainwright & Co.Reiterate Buy -> Buy
2023-02-24HC Wainwright & Co.Reiterate Buy
2022-02-14HC Wainwright & Co.Initiate Buy

Next Earnings Forecast Details

Next Earnings Details

Release DateJun 15, 2026
PeriodQ3 / 2026
EPS Estimate-$2.77
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q83.13%
Number of Analysts2

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%

Next Earnings Summary

BCTX is expected to report earnings on 6/15/2026. The consensus EPS estimate for the next earnings is -2.77 USD and the consensus revenue estimate is 0 USD.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
Revenue
YoY % growth
BCTX revenue by date.BCTX revenue by date.
N/AN/A
380.95%
N/AN/A
EBITDA
YoY % growth
BCTX ebitda by date.BCTX ebitda by date.
N/A-1.688M-2.344M
-38.90%
-3.613M
-54.12%
-4.519M
-25.08%
-3.547M
21.50%
-6.961M
-96.22%
-15.274M
-119.43%
-23.257M
-52.27%
-33.246M
-42.95%
-27.098M
18.49%
N/AN/AN/AN/A
EBIT
YoY % growth
BCTX ebit by date.BCTX ebit by date.
-3.548M-1.689M
52.41%
-2.345M
-38.83%
-3.625M
-54.63%
-4.533M
-25.04%
-3.561M
21.44%
-6.976M
-95.89%
-15.289M
-119.16%
-23.272M
-52.22%
-33.33M
-43.22%
-27.205M
18.38%
N/A
-25.11%
N/A
-27.89%
N/AN/A
Operating Margin
BCTX operating margin by date.BCTX operating margin by date.
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
EPS
YoY % growth
BCTX eps by date.BCTX eps by date.
N/AN/AN/AN/AN/AN/AN/AN/A-195.00
-26.19%
-45.00
76.92%
-128.19
-184.87%
N/A
90.98%
N/A
70.31%
N/A
54.12%
N/A
52.56%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q3 / 26
EPS
Q2Q % growth
-2.77
83.13%
Revenue
Q2Q % growth
EBITDA
Q2Q % growth
N/A
EBIT
Q2Q % growth
-9.393M
-48.43%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

BCTX Yearly Revenue VS EstimatesBCTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2M 4M 6M 8M 10M
BCTX Yearly EPS VS EstimatesBCTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 -50 -100 -150 -200

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
25.73%
EPS Next 5 Year
18.83%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

BRIACELL THERAPEUTICS CORP / BCTX Forecast FAQ

When does BRIACELL THERAPEUTICS CORP (BCTX) report earnings?

BRIACELL THERAPEUTICS CORP (BCTX) will report earnings on 2026-06-15.


Can you provide the consensus estimates for BRIACELL THERAPEUTICS CORP next earnings?

The consensus EPS estimate for the next earnings of BRIACELL THERAPEUTICS CORP (BCTX) is -2.77 USD and the consensus revenue estimate is 0 USD.